Skip to main content

7 Bold and Audacious Predictions for Marijuana Stocks in 2019 - Motley Fool

7 Bold and Audacious Predictions for Marijuana Stocks in 2019 - Motley Fool

Move aside, Nostradamus. There's a new prognosticator in town. Namely, me.

Rather than compose cryptic quatrains about mirky global events far in the future, I'll limit my predictions to one specific area -- marijuana stocks. And I'll make them crystal-ball clear so that they're easy to interpret. Finally, instead of peering into the distant future, my look ahead will focus solely on next year.

So without further ado, here are my seven bold and audacious predictions for marijuana stocks in 2019.

Man holding card with 2019 written on it behind a glass ball.

Image source: Getty Images.

1. U.S. legalizes marijuana -- marijuana stocks soar, Jeff Sessions cries


I predict that Sen. Cory Gardner (R-CO) and Sen. Elizabeth Warren (D-MA) will finally succeed in getting the "Strengthening the Tenth Amendment Through Entrusting States (STATES) Act" passed in the U.S. Senate. A similar bill will pass the House of Representatives, with President Trump quickly signing the legislation into law.

Marijuana stocks then soar so high that some established companies consider including the word "cannabis" in their names. Oh, and former U.S. Attorney General Jeff Sessions cries when interviewed on TV about the marijuana legalization news, spurring the biggest social media meme of the year.

2. At least three $1 billion-plus deals with one CEO eating his words


Canopy Growth (NYSE:CGC) had its $4 billion deal with Constellation Brands in 2018. Cronos Group (NASDAQ:CRON) had its $1.8 billion investment from Altria. Next year, I foresee at least three other deals of more than $1 billion between marijuana growers and companies operating outside of the cannabis industry.

Tilray (NASDAQ:TLRY) might or might not be involved in one of these big deals. Either way, Tilray CEO Brendan Kennedy literally will eat his words by gobbling down a transcript of his 2018 interview with CNBC host Jim Cramer where he stated that the company didn't want to partner with Anheuser-Busch InBev -- it wanted to build another Anheuser-Busch InBev.

Oh, wait... Tilray just announced a partnership with (drum roll please) Anheuser-Busch. Maybe, instead, Kennedy will eat his latest words that Tilray wasn't interested in an investment from its new joint-venture partner.

3. Cannabis-infused beverages market explodes, more popular with millennials than soft drinks


My forecast is that Canada finalizes its regulations for cannabis edibles in 2019, with Canopy Growth and Constellation immediately launching more than a dozen new cannabis-infused beverages. Other companies quickly follow suit. Millennials in Canada spend more on cannabis-infused beverages in the fourth quarter of next year than they do on soft drinks.

Meanwhile, the U.S. hemp-based CBD-infused beverage market also takes off in a major way. Canopy Growth scrambles to enter the fast-growing market before the end of the year in advance of its highly anticipated Super Bowl commercial featuring the Rolling Stones singing a version of one of their biggest hits with revised lyrics, "I can get some satisfaction."

4. First U.S. plant-based cannabinoid drug is a big hit, Big Pharma execs injure themselves after slapping foreheads in regret


Despite some nattering negativism by skeptics, GW Pharmaceuticals' (NASDAQ:GWPH) Epidiolex, the first plant-based cannabinoid drug approved in the U.S., becomes a smashing commercial success. Even pessimistic analysts project that Epidiolex likely will become a blockbuster within a few years.

As Epidiolex sales steadily increase, several renowned Big Pharma executives are forced to receive medical care for injuries received from slapping themselves on the foreheads in regret. These slaps stem from the executives reading the histories of their companies marketing cannabis-based drugs in the early 20th century.

5. At least one Canadian marijuana stock has zero dilution, prompting celebrations in the streets of major Canadian cities


After many major Canadian marijuana stocks diluted themselves to smithereens in 2018, the new year offers a much different scenario. At least one Canadian marijuana producer actually goes the entire year in 2019 without issuing a single new share.

The zero dilution at first stuns investors. However, once the shock wears off, they storm the streets of major Canadian cities in celebration.

6. Mexico contemplates building a wall to prevent an invasion of Canadian marijuana growers


Mexico's Supreme Court overturned the country's ban on recreational marijuana in 2018. I predict that the country's legislators will fully legalize the sale and use of recreational weed in 2019.

Although the country will at first embrace the idea of Canadian marijuana producers flocking to set up shop in Mexico, some politicians won't be happy. A bill is introduced to build a wall along the Mexico-U.S. border to prevent more Canadian marijuana growers from heading south. The bill dies in committee, however, after it receives an official endorsement from U.S. President Donald Trump.

7. Noted short-seller issues update that it liked marijuana stocks all along, was just joking in previous negative attacks


Citron Research and its founder, Andrew Left, caused shares of Cronos Group to plummet in August 2018 with a report titled, Cronos: The Dark Side of the Cannabis Space. Cronos Group, by the way, ended 2018 as one of the best-performing marijuana stocks.

In 2019, my prognostication is that Citron does a complete about-face. It publishes a new online report that states that everything it has said in the past about marijuana stocks was really made in jest. Citron's report also says that estimates of a global marijuana market of $150 billion are off, with the actual number closer to $148 billion.

All kidding aside


My predictions for marijuana stocks in 2019 were obviously made with tongue firmly implanted in cheek. However, there are some aspects of the predictions that I suspect actually will happen next year.

My hunch is that there's a relatively good chance that the STATES bill will pass, for example. While this legislation doesn't really legalize marijuana in the U.S., it would mean that the federal government wouldn't interfere in states that have legalized marijuana for either medical or recreational purposes.

I think there will be more big deals between companies operating outside of the cannabis industry and marijuana producers. The cannabis-infused beverage market likely will get off to a pretty good start in 2019. Epidiolex just might surprise some observers with its early sales momentum.

With its $4 billion cash infusion and revenue picking up, Canopy Growth may not dilute its stock further next year. Mexico could very well legalize recreational cannabis, attracting significant interest from the major Canadian marijuana producers. And while the Citron Research prediction won't be fulfilled, growth in the global cannabis industry could cause the short-seller to set its sights on stocks in other industries.

Here's one more serious prediction as a bonus. Four marijuana stocks were mentioned in my whimsical predictions -- Canopy Growth, Cronos Group, GW Pharmaceuticals, and Tilray. I predict that the biggest marijuana stock winner in 2019 will more than quadruple and will be... none of the above.





Let's block ads! (Why?)



https://www.fool.com/investing/2018/12/2...a-sto.aspx

from potads - All Forums learn more

Popular posts from this blog

Martha Stewart launches CBD line in crowded market - CNN

Martha Stewart launches CBD line in crowded market - CNN The hemp-derived, cannabidiol-rich gummies, soft gels and oil drops officially launched on Thursday after more than a year in development. The products are the result of the style maven's partnership with Canopy Growth ( CGC ) , the Canadian cannabis company with a multibillion-dollar backer in US alcohol giant Constellation Brands ( STZ ) . Stewart joined Canopy as an adviser in early 2019 for the express purpose of developing cannabis products for humans and their pets after being introduced to Canopy's founder by her friend Calvin Broadus Jr. -- the rapper and businessman better known as Snoop Dogg. His Leafs by Snoop cannabis brand is produced by Canopy. The initial Martha Stewart CBD products, which range from $34.99 to $44.99, will be sold online at Canopy's e-commerce site . The pet products are expected to debut later this year. "I was surprised to learn that while most people have heard of

This UK-Based Entrepreneur Has Mastered the Art of Entrepreneurship - Entrepreneur

This UK-Based Entrepreneur Has Mastered the Art of Entrepreneurship - Entrepreneur June 20, 2020 5 min read Opinions expressed by Entrepreneur contributors are their own. All businesses hinge on the success of their founders. With their unique blend of innovation and brilliance, successful entrepreneurs can transform their industries by filling a gap in the market. This is what Vithurs (or V, as he likes to be called) did when he entered the digital marketing world and ultimately launched Blessed CBD —one of the fastest growing CBD brands in the UK. His unique skill set, paired with his fearless approach to business and deep knowledge of the cannabis industry, propelled him towards success. Because ultimately, a company is only as successful as its founder. And there’s no arguing Vithurs is a leading name in the UK’s growing cannabis industry. Global reach in digital marketing Born and raised in the UK, Vithurs was just 13 when he delved into Internet marketing f

The Half-Legal Cannabis Trap - POLITICO

The Half-Legal Cannabis Trap - POLITICO LOS ANGELES — Everything about Kelvin’s job in a neighborhood southwest of downtown seemed like any other assignment, if not a little more exciting. The 40-year-old, who had previously worked as an electrician, had been employed since 2015 by a private security company that contracted him out to guard marijuana dispensaries. In 2019, he was protecting one of the thousand or so cannabis stores in California’s biggest city—part of an industry that has grown less and less underground since 1996, when the state first legalized medical marijuana. Kelvin, who asked not to be identified beyond his middle name to avoid professional retaliation, doesn’t smoke pot, but says the gig felt like the future. He grew up in a time when other Black people he knew in Los Angeles would go to jail for possessing even small amounts of the drug. Now, customers could walk into shops like the one he was guarding, many of which can be identified by green crosses on